Search
Luvometinib
go.drugbank.com/drugs/DB21696InvestigationalLuvometinib has a monoisotopic molecular weight of 665.04 Da.
Pebezertinib
go.drugbank.com/drugs/DB21705InvestigationalPebezertinib has a monoisotopic molecular weight of 497.16 Da.
Inlexisertib
go.drugbank.com/drugs/DB21713InvestigationalInlexisertib has a monoisotopic molecular weight of 535.29 Da.
MBO7133
go.drugbank.com/drugs/DB04999ExperimentalHigher doses of araC cannot be used to overcome this limitation due to bone marrow toxicity resulting from rapid activation in that tissue. … However, araC is only slowly converted to araCTP in the liver or in primary liver tumors due to low levels of an enzyme in the liver that is required for the conversion of araC to araCMP, the first step
Tebentafusp
go.drugbank.com/drugs/DB15283ApprovedInvestigational[L39995] Tebentafusp was subsequently approved for the same indication in the EU in April 2022.[L41675]
Rifamycin
go.drugbank.com/drugs/DB11753ApprovedInvestigationalWithdrawn[L4800] This drug was also sent for review to the EMA in 2015 by Dr. Falk Pharma Gmbh and it was granted a waiver for the tested conditions.[L4801]
Umbralisib
go.drugbank.com/drugs/DB14989ApprovedInvestigationalWithdrawnWhile it initially offered a promising therapy for patients experiencing relapsing or refractory disease,[A229363] umbralisib was withdrawn from the market due to safety concerns as the drug was associated
MVA-SARS-2-S
go.drugbank.com/drugs/DB16432InvestigationalMVA is a highly attenuated poxvirus vector[A226603] that has a high-level of biological safety due to its quality of being a non-replicating virus in mammalian hosts[L30458] and is used to develop vaccines
Faxeladol
go.drugbank.com/drugs/DB20529InvestigationalFaxeladol has a monoisotopic molecular weight of 233.18 Da.
Vevorisertib
go.drugbank.com/drugs/DB21481InvestigationalVevorisertib has a monoisotopic molecular weight of 586.32 Da.